Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
By sending nanoemulsion formulations on a space flight, scientists are investigating whether chitosan—a material derived from ...
We came across a bullish thesis on Rocket Pharmaceuticals, Inc. (RCKT) on Twitter by sharkbiotech. In this article, we will ...
Varda, a US firm planning to manufacture pharmaceuticals in low Earth orbit, is expecting its second capsule to return to ...
Zacks Investment Research on MSN4d
AMGN's Eczema Drug Meets Goal in Two Late-Stage StudiesAmgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Shares in Rocket Pharmaceuticals have been living up to their name, shooting up following encouraging early-stage clinical trial results from a gene therapy for a serious inherited rare heart disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback